Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
11 mars 2025 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
24 févr. 2025 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
10 janv. 2025 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
13 déc. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
11 déc. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
11 déc. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degr
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
05 déc. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
26 nov. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
13 nov. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference